Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application

• Published in: Applied microbiology and biotechnology Vol. 100; no. 20; pp. 8693 - 8699
• Main Authors: Ou, Bingming, Yang, Ying, Tham, Wai Liang, Chen, Lin, Guo, Jitao, Zhu, Guoqiang
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2016; Springer; Springer Nature B.V
• Subjects: Analysis; Antigens; Bacteria; Biomedical and Life Sciences; Biotechnology; Chromosomes; E coli; Escherichia coli; Escherichia coli - genetics; Escherichia coli - immunology; Escherichia coli - metabolism; Genetic aspects; Genetic Engineering; Genetically modified organisms; Genetics; Laboratories; Life Sciences; Melanoma; Microbial Genetics and Genomics; Microbiology; Mini-Review; Peptides; Physical properties; Plasmids; Probiotics; Probiotics - administration & dosage; Proteins; Studies; Tumors; Vaccines; Vaccines, Synthetic - genetics; Vaccines, Synthetic - immunology; Vectors (Biology); Zoonoses; China; Chromosome; Clinical application; Nissle 1917; Cryptic plasmids; Genetic modification
• ISSN: 0175-7598; 1432-0614
• DOI: 10.1007/s00253-016-7829-5

Escherichia coli strain Nissle 1917 (EcN) has been used as a probiotic. Genetic engineering has enhanced the utility of EcN in several vaccine and pharmaceutical preparations. We discuss in this mini review the genetics and physical properties of EcN. We also discuss the numerous genetic engineering strategies employed for EcN-based vaccine development, including recombinant plasmid transfer, genetic engineering of cryptic plasmids or the EcN chromosome, EcN bacterial ghosts and its outer membrane vesicles. We also provide a current update on the progress and the challenges regarding the use of EcN in vaccine development.